Risk-guided Disease managEment Plan to prevEnt CAD in Patients Treated With Previous Cancer (REDEEM-CAD)

November 27, 2025 updated by: Baker Heart and Diabetes Institute

Risk-guided Disease managEment Plan to prevEnt CAD in Patients Treated With Previous Cancer (REDEEM-CAD)

REDEEM-CAD is a prospective multi-centre study of CAD risk evaluation and management in cancer survivors 40-70 years with chemotherapy or radiotherapy >5 years ago.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

REDEEM-CAD is a prospective multi-centre study in which a process of evaluating the risk of coronary artery disease is studied in cancer survivors 40-70 years with chemotherapy or radiotherapy >5 years ago. The efficacy of this CAD risk evaluation will be compared with the broad community in two existing studies - CAUGHT-CAD and EDCAD. This unique Screening/Management Plan (SMP) has 2 components; 1) A novel clinical and imaging-based screening algorithm to select those most likely to develop coronary artery disease, 2) A clinical review to ensure optimal risk factor control and cardio protection.

Follow-up of treated patients will continue for an average of 36 months, with clinic reviews at 12, 24 and 36 months. The results will define the prevalence of subclinical coronary artery disease, and the feasibility and the efficacy of the SMP.

Study Type

Observational

Enrollment (Estimated)

748

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

40 years to 70 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Cancer survivors 40-70 years with chemotherapy or radiotherapy >5 years ago

Description

Inclusion Criteria:

A history of cancer >5 y ago associated with potential cardiotoxicity from chemotherapy and/or radiotherapy (chiefly survivors of breast cancer, Hodgkin's lymphoma and prostate cancer).

Exclusion Criteria:

  • Unable to provide written informed consent to participate in this study
  • Known coronary artery disease at recruitment
  • History of previous coronary artery disease
  • Inability to acquire interpretable CT images
  • Contraindications/Intolerance to or already taking statin therapy
  • Oncologic (or other) life expectancy <12 months or any other medical condition (including pregnancy) that results in the belief (deemed by the Chief Investigators) that it is not appropriate for the patient to participate in this trial

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Survivor Screening/Management Plan

In cancer survivors;

  1. A novel clinical and CT imaging-based screening algorithm to select those most likely to develop coronary artery disease,
  2. A clinical review to ensure optimal risk factor control and cardiac protection.
Diagnostic test: Coronary CT
Screening/Management Plan
Non-cancer Screening/Management Plan

In matched non-cancer patients (from EDCAD trial);

  1. A novel clinical and CT imaging-based screening algorithm to select those most likely to develop coronary artery disease,
  2. A clinical review to ensure optimal risk factor control and cardiac protection.
Diagnostic test: Coronary CT
Screening/Management Plan

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of evaluated patients who should undergo CAD prevention
Time Frame: 3 years
High clinical risk, or intermediate risk with CAC score >0
3 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion with critical CAD
Time Frame: 3 years
Coronary stenosis >70% by CT coronary angiogram
3 years
Proportion at intermediate clinical risk
Time Frame: 3 years
Intermediate clinical risk (0.8-2.0% annualized risk by Pooled Cohort Equation)
3 years
Statin responsiveness
Time Frame: 3 year follow-up
Change in plaque volume
3 year follow-up

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Baker Heart and Diabetes Institute

Collaborators

The Alfred
Peter MacCallum Cancer Centre, Australia
Menzies Institute for Medical Research
Northern Hospital, Australia
Western Health, Australia

Investigators

  • Principal Investigator: Tom Marwick, MBBS,PhD,MPH, Baker Heart and Diabetes Institute

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 18, 2023

Primary Completion (Estimated)

May 1, 2026

Study Completion (Estimated)

May 1, 2026

Study Registration Dates

First Submitted

May 4, 2022

First Submitted That Met QC Criteria

May 4, 2022

First Posted (Actual)

May 9, 2022

Study Record Updates

Last Update Posted (Estimated)

December 4, 2025

Last Update Submitted That Met QC Criteria

November 27, 2025

Last Verified

September 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 134-22

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Coronary Artery Disease

Clinical Trials on Coronary CT

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Armenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe